Rhythm's Q2 2026 Preview: Can IMCIVREE Real-World Takeoff Offset the $40M Sales Gap?

Q2 matters because the launch needs proof beyond the headline

IMCIVREE may be gaining real-world traction, but Q2 still has to explain roughly a $40 million sales gap versus expectations. That is the core stake. Rhythm already said it launched in the U.S. for acquired HO and collected more than 150 patient start forms in the first six weeks. That is a reasonable start, but investors still need evidence that early interest is turning into usable prescription momentum.

What matters most is not perfect sales math. It is whether prescribers are actually starting patients, keeping them on therapy, and broadening use beyond a small early group.

The bullish case is straightforward: this is an expansion into a new indication, not a leap into an unknown market. Rhythm entered the quarter with First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million, so there is already a working commercial base. The early patient-start data suggest clinicians see value in the product. If that is true, Q2 can still look uneven and be consistent with a slow ramp.

The bearish case is just as straightforward. Commercial execution matters more than theory. A strong opening can fade if access is difficult or specialists remain cautious. Madrigal offers a useful contrast: Madrigal Q2 Rezdiffra sales reached $364.3 million. The takeaway is not the dollar gap itself. It is that investors in this part of the market want proof that a drug is being prescribed, started, and maintained-not just a promising launch announcement.

IMCIVREE launch read: starts look promising, but revenue still has to follow

Patient starts are the first real-world checkpoint

The clearest reality check is not a projection. It is whether patients are actually getting started on the drug. Rhythm said it collected more than 150 patient start forms in the first six weeks after the acquired HO approval. That matters because starts sit closer to actual clinical use than revenue does. They suggest prescribers see a role for the medicine and that patients are willing to go through the onboarding process.

That does not guarantee a fast commercial ramp. Launches can stall after the first month if prior authorization slows access, refills are weak, or early adopters hesitate. But it does show that this is not a launch without any evidence of use.

Europe adds a smaller but still useful signal. Rhythm said IMCIVREE received European Commission authorization for acquired HO. That does not solve the U.S. quarter, but it does support the idea that the same unmet need is being recognized in more than one market.

ENDO data can support the franchise story without proving sales

This is where the bull case can broaden. Earlier this month, Rhythm said it would present ENDO 2026 data across acquired HO, BBS, and PWS. That matters because each indication is another potential patient pool for the same drug class. If setmelanotide shows benefit across more obesity-related conditions, investors have more reasons to believe the franchise could expand over time.

The key caveat is that conference data is not the same as prescription volume. Poster sessions and interim updates can shift sentiment, but they do not replace launch execution. ENDO is useful for building belief; it is not proof of sales.

Madrigal also offers a useful reminder about commercial friction. Its Rezdiffra sales reached $364.3 million in Q2, showing that the market will reward real adoption. But its label also carries hepatotoxicity and gallbladder adverse reactions. The lesson is not about the competitor itself. It is that even successful drugs can face safety and monitoring hurdles that slow physicians down. In a niche indication like acquired HO, access and safety logistics can matter a lot.

So the read is a cautious green light: patient starts look encouraging, but commercial follow-through still has to be proven.

What would make RYTM more compelling into Q2 earnings

For investors, the timing is simple: Rhythm's next quarterly release after Q1 is Q2, which keeps the main scoreboard in the October earnings window. That makes this less of a distant biotech bet and more of a near-term earnings watch. If the acquired HO launch is turning into real-world use, management should be able to show it on the call. If not, the stock risks drifting back to the older critique: promising science, later revenue.

The rerating path is not complicated. Madrigal has more than 49,000 patients on Rezdiffra. Rhythm does not need anywhere near that scale right away. It needs the same basic proof that a rare-disease drug is being written, started, and continued. And because ENDO 2026 data across acquired HO, BBS, and PWS is already available, RYTM could get upside from science before sales fully catch up.

Three scoreboard items

• Prescriber spread. Patient starts are useful, but investors need evidence the drug is moving beyond a handful of early centers.

• Access and follow-through. This is the part that often decides the stock. Management needs to sound credible on onboarding, coverage, and whether early starts can become continued use.

• Clinical reinforcement. Trial updates do not have to be game-changing to matter. They just need to strengthen the case that demand will hold up over time.

If management cannot show broader adoption, cleaner monetization from the new approval, or trial updates that strengthen near-term demand, the launch story weakens quickly.

RYTM can still move on good science before it moves on good sales, but the quarter still has to prove the commercial engine is turning.